OTR3® is a biotechnology company conceived by Professors Denis Barritault and Jean-Pierre Caruelle from the University of Paris-East in 2000, laureates of the French national competition for the creation of the best innovative company. Known for their pioneering work on Growth Factors – the discovery of FGF, HARP/PTN – they invented the RGTA® Technology (ReGeneraTing Agents), a new therapeutic class in regenerative medicine.
The RGTA® Technology is patent protected worldwide.
OTR3® has currently 2 products, CACIPLIQ20® and CACICOL20®, which are sold in Europe and other countries worldwide as medical devices.
OTR3® is NF EN ISO 13485 certified.
The goal of OTR3® is to continue advancing in the RGTA® Technology, developing new indications and innovative healthcare products. Our expansion relies on specific research and development studies that will take into account the biological and pharmaceutical needs specific to each therapeutic indication.
As an initiative, OTR3® is invested in developing a wider range of indications for its current products, each based on molecules suitable for the treatment of various diseases.
The commercialization of all our products is entrusted to pharmaceutical companies through licensing or distribution agreements.